Background Mean platelet volume (MPV) has been known to be a marker of platelet activity and influenced by inflammation.The correlations of MPV with disease activities were reported in several rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis. However MPV is controversial as a marker of their disease activities. Furthermore, the association of MPV with disease activity in Behcet's disease (BD) is not determined yet. Objectives The aim of this study is to investigate the association of MPV with clinical manifestations and disease activity in BD. Methods We sequentially retrieved data on 193 patients with BD who visited to our rheumatic clinic from 1999 to 2013 by reviewing of medical records. BD was diagnosed according to International Criteria for BD. The data on demographics, clinical manifestations, and laboratory results including MPV, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were collected. Active BD was defined as it needed prednisolone of more than 0.5 mg/kg/day or to add immunosuppressive agents. Infection was demonstrated by culture or clinical improvement with antibiotic treatment. Statistical analysis was made by t-test and Pearson's correlation. A value of p<0.05 was considered as statistically significant. Results The ratio of female to male was 2:1 and the age of symptom onset was 32.2±11.1 years. The age at diagnosis of BD was 40.9±10.0 years and the follow-up duration was 4.7±3.8 years. Fifty-one patients (26.4%) had major organ involvements such as eye (17.6%), gastrointestinal (7.8%), vascular (4.7%) and nervous system (3.1%). MPV at diagnosis was 8.2±1.2 fl. MPV was not related with clinical manifestations, ESR and CRP. During follow-up, 79 patients had active BD and 12 patients had infections such as pulmonary tuberculosis and pyelonephritis. MPV in active BD (8.1±1.4 fl) was lower than that in inactive disease (8.9±1.3 fl; (p<0.0001). MPV significantly increased when the patients were infected (9.5±1.6 fl; p<0.0001) Conclusions MPV was not related with clinical manifestations of BD. However, there was an association of active BD with lower MPV and of infection with higher MPV. Thus, MPV level may be used as a marker of BD activity and to differentiate infection from active BD. References Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012 Dec;44(8):805-16. Mean platelet volume in recurrent aphthous stomatitis and behcet disease. Angiology. 2014 Feb;65(2):161-5. Increased mean platelet volume in Behçet's disease with thrombotic tendency. Tohoku J Exp Med. 2010 Jun;221(2):119-23. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5121
Background Axial spondyloarthritis (aSpA) is a chronic inflammatory disease that can lead to irreversible spinal bone damage and loss of spine mobility. However, it is controversial whether the inflammation is coupled with bony change in aSpA. C-reactive protein (CRP) is useful for monitoring disease activity, if it is elevated at baseline. Objectives To investigate the association of CRP with radiographic spinal progression in aSpA Methods We reviewed the data of 178 patients with aSpA who visited the rheumatology clinic at our hospital between January 2009 and February 2013. They had at least 2 sets of lateral cervical and lumbar radiographs a minimum of two years apart for assessing the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). We calculated annual mSASSS change using two different mSASSS. CRP's at the time of taking radiographs were also collected. High CRP was defined as it was ≥10 mg/L. We divided the patients into 4 groups in terms of CRP at baseline and follow-up during treatment: persistently low (LL), persistently high (HH), decreased CRP to low level after treatment (HL), and increased CRP after treatment (LH). Results Age of the patients was 40.2±12.0 years and female to male was 1:4. Disease duration was 13.3±9.0 years. The patients with HLA-B27 positivity were 91%; those with ankylosing spondylitis were 81%. Radiographs were taken at intervals of 4.5±2.6 years. Seventy four patients were included in LL, 27 in HH, 55 in HL and 5 in LH. The duration of decrease of CRP to low level was 8.9±10.7 months in HL. (Among In the patients of LL, the frequencies of male, initial spinal syndesmophytes, and use of TNF inhibitors decreased compared with other groups.) New spinal syndesmophytes were observed during follow-up in 24% (LL), 44% (HH), 56% (HL) and 40% (LH). Annual mSASSS change was 0.6±1.0 (LL), 1.4±1.5 (HH), 1.5±1.6 (HL), and 0.6±0.8 (LD). The patient with initial high CRP showed significantly more new syndesmophyes and annual mSASSS change than those with initial low CRP. When the patient with high CRP were classified to two groups (48 patients in 10≤ and <30 mg/L, and 37 patients in ≥30 mg/L), however, there was no statistical difference new syndesmophyes and annual mSASSS change between them. Comparing HH and HL, annual mSASSS change did not differ between them. Although it was not statistically significant, new syndesmophytes were more common in HL than in HH. Conclusions Baseline high CRP (≥10 mg/L) is associated with radiographic spinal progression compared with low CRP. However, the higher CRP was not correlated with the more progressive spinal disease. In addition, there was no difference in spinal bony change between the patients with persistent high CRP and those with a reduction of CRP. Thus, while monitoring the aSpA patients with high baseline CRP, physicians should keep in mind that a decrease in CRP does not guarantee favorable treatment response enough to retard bony progression. Further disease-modifying drugs may be needed to be given for them. Disclosure...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.